Vogelzang et al. recently reviewed new agents that under evaluation for the treatment of MM, including EGFR, PDGFR, VEGF and HGF inhibitors, inhibitors of mTOR, a downstream molecule of the PI3K/AKT pathway, and inhibitors of the proteasome/ubiquitin pathway (Vogelzang, 2005). The gene discussed is MTOR; the disease is Miyoshi myopathy.